Sivade Aurélie, Bensaid Djamila, Monnier Yan, Shabafrouz Keyvan, Bouchaab Hanan, Cristina Valérie
Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne.
Service d'ORL et de chirurgie cervico-faciale, Département des services de chirurgie et d'anesthésiologie, CHUV, 1011 Lausanne.
Rev Med Suisse. 2017 May 17;13(563):1029-1031.
Immunotherapy, especially checkpoint inhibitors such as anti-PD1 and anti-PDL1 antibodies, has changed the standard of care and the prognosis of melanoma, but also more recently of lung cancer, renal cancer and Hodgkin lymphoma. Results of preliminary studies in head and neck squamous cell carcinoma (HNSCC) as well as in less frequent tumors of the region, such as nasopharyngeal carcinoma and high grade salivary gland carcinoma, are also promising. Indeed, in a recent phase 3 study, the PD1 inhibitor nivolumab has recently demonstrated a significant improvement in overall survival for platin-resistant recurrent and/or metastatic HNSCC.
免疫疗法，尤其是诸如抗PD1和抗PDL1抗体等检查点抑制剂，已经改变了黑色素瘤的治疗标准和预后，而且最近也改变了肺癌、肾癌和霍奇金淋巴瘤的治疗标准和预后。头颈部鳞状细胞癌（HNSCC）以及该区域较少见肿瘤（如鼻咽癌和高级别唾液腺癌）的初步研究结果也很有前景。事实上，在最近一项3期研究中，PD1抑制剂纳武单抗最近已证明对铂类耐药的复发和/或转移性HNSCC的总生存期有显著改善。
